Finance

Lists
Why is 128940 down 2,01%?
Dive Deeper
128940:KRX
Hanmi Pharm Co Ltd
389 500,00 KRW
-2,01%
(-8 000,00) 1D
19 ოქტ, 15:30:05 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 128940...
Open
389 500 KRW
High
394 500 KRW
Low
370 000 KRW
Mkt. cap
4,99 ტრლ.
Avg. vol.
124,40 ათ.
Volume
102,10 ათ.
Dividend
0,51%
Quarterly dividend
500 KRW
Ex-dividend date
30 მარ. 2026
P/E ratio
22,78
52-wk high
647 000 KRW
52-wk low
302 000 KRW
EPS
17 100 KRW
Shares outstanding
12,81 მლნ.
No. of employees
2 ათ.
Open
389 500 KRW
High
394 500 KRW
Low
370 000 KRW
Mkt. cap
4,99 ტრლ.
Avg. vol.
124,40 ათ.
Volume
102,10 ათ.
Dividend
0,51%
Quarterly dividend
500 KRW
Ex-dividend date
30 მარ. 2026
P/E ratio
22,78
52-wk high
647 000 KRW
52-wk low
302 000 KRW
EPS
17 100 KRW
Shares outstanding
12,81 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul. Wikipedia
About Hanmi Pharm Co Ltd
CEO-
Employees2,34 ათ.
Founded1973
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
362,35 მლრ.
432,96 მლრ.
392,93 მლრ.
467,25 მლრ.
Cost of goods sold
156,75 მლრ.
172,48 მლრ.
175,64 მლრ.
164,04 მლრ.
Cost of revenue
156,75 მლრ.
172,48 მლრ.
175,64 მლრ.
164,04 მლრ.
Research and development expenses
54,65 მლრდ.
51,66 მლრდ.
57,12 მლრდ.
52,08 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
95,88 მლრდ.
125,55 მლრ.
106,52 მლრ.
120,03 მლრ.
Operating expense
153,33 მლრ.
205,73 მლრ.
171,55 მლრ.
179,72 მლრ.
Total operating expenses
310,08 მლრ.
378,22 მლრ.
347,19 მლრ.
343,76 მლრ.
Operating income
52,27 მლრდ.
54,74 მლრდ.
45,74 მლრდ.
123,49 მლრ.
Other non operating income
-1,73 მლრდ.
664,20 მლნ.
2,62 მლრდ.
-4,88 მლრდ.
EBT including unusual items
52,26 მლრდ.
58,49 მლრდ.
55,38 მლრდ.
120,14 მლრ.
EBT excluding unusual items
51,55 მლრდ.
57,99 მლრდ.
55,26 მლრდ.
119,61 მლრ.
Income tax expense
6,85 მლრდ.
4,43 მლრდ.
4,30 მლრდ.
36,06 მლრდ.
Effective tax rate
13,10%
7,58%
7,76%
30,01%
Other operating expenses
-
-
-
-
Net income
40,13 მლრდ.
48,12 მლრდ.
45,49 მლრდ.
83,31 მლრდ.
Net profit margin
11,07%
11,11%
11,58%
17,83%
Earnings per share
-
-
-
-
Interest and investment income
1,67 მლრდ.
2,51 მლრდ.
2,62 მლრდ.
2,77 მლრდ.
Interest expense
-3,94 მლრდ.
-3,65 მლრდ.
-3,41 მლრდ.
-3,35 მლრდ.
Net interest expenses
-2,27 მლრდ.
-1,14 მლრდ.
-783,67 მლნ.
-588,23 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
76,84 მლრდ.
80,03 მლრდ.
70,44 მლრდ.
148,58 მლრ.
Gain or loss from assets sale
-13,32 მლნ.
-39,36 მლნ.
3,68 მლნ.
40,66 მლნ.
AI content may include mistakes. Learn more
Google აპები